Trading Halt
Released
Released
Announcement PDF
Market Announcement
3 November 2023
Race Oncology Limited (ASX: RAC) – Trading Halt
Description
The securities of Race Oncology Limited (‘RAC’) will be placed in trading halt at the request of RAC, pending it
releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the
earlier of the commencement of normal trading on Tuesday, 7 November 2023 or when the announcement is
released to the market.
Issued by
Lisa Banh
Senior Adviser, Listings Compliance
3 November 2023
ASX Limited
Market Announcement 1/1
ASX Customer Service Centre 131 279 | asx.com.au
3 November 2023
Ms Lisa Bahn
Adviser Listings, ASX Compliance (Sydney)
Australian Securities Exchange Limited
20 Bridge Street
SYDNEY NSW 2000
By email: tradinghaltssydney@asx.com.au
Request for Trading Halt
Race Oncology Limited (ASX: RAC) (Race) requests an immediate trading halt be granted in respect of its
shares on Friday, 3 November 2023.
The trading halt is requested to allow analysis and interpretation of data received relating to an
investigator-initiated Phase 2 human clinical trial, where Race’s lead asset, bisantrene, is being studied in
patients with Acute Myeloid Leukaemia.
In accordance with ASX Listing Rule 17.1, Race provides the following information:
(a)
the trading halt is necessary for Race to analyse and interpret data and make an announcement in
relation to an investigator-initiated Phase 2 human clinical trial;
(b)
the trading halt should remain in place until the earlier of the Company making an announcement
in relation to the above matter or the commencement of trading on Tuesday, 7 November 2023;
(c)
Race is not aware of any reason why the trading halt should not be granted; and
(d)
Race is not aware of any other information necessary to inform the market about the trading halt.
Yours sincerely
Peter Webse
Company Secretary
Authorised for the release by the Board.
Race Oncology Ltd ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • raceoncology.com
Share your feedback
Discover